Q-omics provides the consensus-scored RAB33B profile across patient tissues and cancer cell-line models. RAB33B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB33B is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, RAB33B RNA expression shows 19,968 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LUSC, and ACC as cancer lineages where RAB33B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB33B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB33B survival associations across molecular data types. RAB33B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB33B RNA expression–survival associations across cancer types. High RAB33B expression shows unfavorable associations in LGG, UVM and ESCA, but favorable associations in KIRC, SKCM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB33B RNA expression.
This table summarizes RAB33B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB33B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB33B shows lower tumor expression in LUSC, UCEC, LUAD, KICH and THCA and higher tumor expression in HNSC. The LUSC box plot shows higher RAB33B RNA expression in normal versus tumor tissue (log2 FC = −0.715, t-test p < 0.001).
This table shows molecular features associated with RAB33B in patient tissues and cancer cell lines. In patient samples, RAB33B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB33B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
